Asciminib: a new therapeutic option in chronic-phase CML with treatment failure-Reference-Cited by-同舟云学术

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure

Published:2022-06-16 Issue:24 Volume:139 Page:3474-3479
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Yeung David T.¹²³^ORCID,Shanmuganathan Naranie¹²³^ORCID,Hughes Timothy P.¹²³

Affiliation:

1. 1Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia;

2. 2Adelaide Medical School, University of Adelaide, Adelaide, Australia; and

3. 3Haematology Department, Royal Adelaide Hospital, Adelaide, Australia

Abstract

Abstract Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase activity, is now approved for the treatment of patients with chronic-phase chronic myeloid leukemia who failed 2 lines of therapy or in patients with the T315I mutation. Promising attributes include high specificity and potency against BCR::ABL1, activity against most kinase domain mutations, and potential for combination therapy with ATP-competitive tyrosine kinase inhibitors. Clinicians now have expanded third-line options, which in most cases will involve a choice between asciminib and ponatinib.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/139/24/3474/1902033/bloodbld2021014689c.pdf

Reference26 articles.

1. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions;Bruford;Leukemia.,2021

2. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1;Schoepfer;J Med Chem.,2018

3. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1;Wylie;Nature.,2017

4. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase;Manley;Leuk Res.,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiplexed experimental strategies for fragment library screening against challenging drug targets using SPR biosensors;SLAS Discovery;2024-01

2. In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile;Leukemia;2023-12-28

3. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia;Pharmaceutics;2023-10-26

4. Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway;Toxicology and Applied Pharmacology;2023-09

5. Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers;European Journal of Medicinal Chemistry;2023-09